NEWS RELEASES


2010	06.08	OctoPlus announces 2010 first half-year results
	12.07	OctoPlus signs drug development contract with The Medicines Company
	08.07	OctoPlus announces agreement with a US biotechnology company on its controlled release technology
	30.06	OctoPlus announces agreement with a major pharmaceutical company on its controlled release technology
	19.05	OctoPlus publishes first quarter business update
	12.05	Shareholders OctoPlus appoint Susan Swarte to Executive Board and Nancy de Ruiter to Supervisory Board
	19.04	OctoPlus' licensee Biolex makes third presentation at EASL confirming Locteron's superior product profile
	16.04	Improved tolerability profile of Locteron confirmed by data presented at EASL conference
	15.04	Locteron data presented at EASL conference show 65% reduction in flu-like side effects with comparable efficacy in hepatitis C
	12.04	OctoPlus publishes Annual Report 2009
	18.03	OctoPlus announces 2009 annual results meeting revenue guidance of Euro 19 million
	16.03	OctoPlus announces update on publication of positive Locteron interim Phase IIb data
	16.03	OctoPlus announces publication of positive Locteron interim Phase IIb data
	08.03	OctoPlus publishes prospectus for listing of shares issued on 18 December 2009
	10.02	OctoPlus announces that Locteron interim Phase IIb data have been accepted for oral and poster presentations at International Liver Congress in April

2009	18.12	OctoPlus announces successful equity raising of € 4 million to strengthen its financial position
	09.11	OctoPlus publishes third quarter business update
	24.09	OctoPlus announces further efficiency measures
	14.09	OctoPlus signs service contract with Axentis Pharma
	08.09	OctoPlus wins expansion of drug delivery evaluation contract with existing client
	26.08	OctoPlus announces change in Executive Board
	12.08	OctoPlus wins new service contract
	06.08	OctoPlus announces 2009 first half-year results
	29.06	OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
	29.06	OctoPlus appoints Susan Swarte as Chief Financial Officer
	23.06	OctoPlus opens new GMP manufacturing facility
	04.06	OctoPlus wins new drug delivery evaluation contract for two compounds
	02.06	OctoPlus to present at two investor conferences in June
	19.05	OctoPlus publishes business update
	24.04	OctoPlus' licensee Biolex presents Locteron Phase IIa results at EASL conference
	23.04	Shareholders OctoPlus appoint James Gale to Supervisory Board
	20.04	OctoPlus' licensee Biolex commences Phase IIb study with Locteron
	06.04	OctoPlus wins new drug delivery evaluation contract
	30.03	OctoPlus publishes Annual Report 2008 and reiterates revised strategy for 2009
	05.03	OctoPlus gives update on shareholdings following its recent fundraising
	27.02	OctoPlus successfully completes equity raising of 6 million euro
	19.02	OctoPlus announces 2008 annual results
	12.02	OctoPlus signs service contract with Galapagos
	30.01	OctoPlus announces change in Executive Board

2008	22.12	OctoPlus wins new technology evaluation contract
	12.11	OctoPlus wins new drug delivery evaluation contract
	06.11	Shareholders Meeting OctoPlus appoints new Executive Board and Supervisory Directors
	04.11	OctoPlus to present at Rodman and Renshaw conference
	16.10	OctoPlus announces 2008 first half-year results and publication of 2007 Annual Report
	10.10	OctoPlus announces dates for AGM and for publication of 2007 Annual Report and 2008 half-year results
	06.10	OctoPlus announces exclusive license and manufacturing agreement for Locteron with Biolex allowing for revenues in excess of 100 million euro
	16.09	OctoPlus announces the nomination of expanded Executive Board
	03.09	OctoPlus obtains additional 0.75 million euro
	31.07	OctoPlus postpones publication of 2008 half-year results until publication of 2007 Annual Report
	28.07	OctoPlus proves efficacy of OP-145 in Phase II ear infection study
	11.07	OctoPlus obtains additional 2 million euro bridge financing
	30.05	Extension of period for preparation of OctoPlus' 2007 annual accounts approved by Extraordinary General Meeting of Shareholders
	15.05	OctoPlus to hold Extraordinary General Meeting of Shareholders on 30 May
	24.04	OctoPlus presents positive Locteron Phase IIa study results at EASL conference
	28.03	OctoPlus obtains bridge financing
	12.03	OctoPlus announces publication of Phase I Locteron results in the Journal of Interferon and Cytokine Research
	22.02	OctoPlus announces 2007 annual results
	07.02	OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C

2007	09.11	Follow-on offering
	06.11	OctoPlus presents positive Phase IIa study results for Locteron in hepatitis C at AASLD conference
	12.10	OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
	26.09	OctoPlus in-licenses diabetes product candidate
	03.08	OctoPlus announces 2007 first half-year results
	29.07	OctoPlus to release 2007 first half-year results on Friday 3 August
	26.07	OctoPlus announces promising results for Locteron Phase IIa clinical study
	15.05	OctoPlus to present at SNS Small & Mid Cap Seminar
	13.05	OctoPlus to present at BioEquity Europe 2007 Conference
	08.05	OctoPlus to present at Rodman & Renshaw Annual Global Healthcare Conference
	27.04	OctoPlus announces analyst meeting on May 1
	25.04	OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis
	24.04	OctoPlus to present at Fortis Bank Biotechnology Conference
	23.04	OctoPlus appoints new Scientific Advisory Board members
	16.04	OctoPlus to present at London Biotech Investment Forum
	30.03	OctoPlus publishes Annual Report 2006
	22.03	OctoPlus to present at BioCapital Europe conference
	06.03	OctoPlus to present at Cowen Health Care Conference
	15.02	OctoPlus announces 2006 annual results
	12.02	OctoPlus to release 2006 year results on Thursday 15 February
	30.01	OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C
	10.01	OctoPlus announces opening of Boston office

2006	29.11	OctoPlus to present at European Venture Summit
	22.11	OctoPlus grants Green Cross Corporation exclusive Korean license to OP-145
	10.11	OctoPlus announces start of construction of expanded facilities
	01.11	OctoPlus to present at Cowen conference and BIO-Europe
	05.07	OctoPlus obtains full rights to OP-145 for the treatment of chronic middle ear infection and other indications
	27.04	OctoPlus presents positive results of Locteron Phase I study
	07.03	OctoPlus initiates Phase II clinical trials with OP-145 in chronic middle ear infection and presents positive Phase I results
	16.01	OctoPlus strengthens its senior management team

2005	02.11	OctoPlus initiates clinical trials with Locteron™, controlled release formulation of alfa interferon
	26.09	OctoPlus and SingVax announce collaboration to develop single-shot Japanese encephalitis vaccine
	17.02	OctoPlus and Biolex announce joint development of Locteron
	20.01	OctoPlus secures Euro 18.25 million in second financing round

2004	21.10	OctoPlus and InnoCore to partner on a novel drug delivery platform for peptides and small molecules
	29.06	OctoPlus grants SurModics access to two biodegradable polymer families for medical device applications
	09.02	OctoPlus reports first clinical proof of concept with OctoDEX
	15.01	OctoPlus and Leiden University Medical Center to start patient trials with novel drug against chronic middle ear infection

2003	14.05	IsoTis and OctoPlus conclude transfer of drug delivery spin-off Chienna
	21.02	OctoPlus announces intended acquisition of drug delivery company Chienna from IsoTis

2002	22.07	OctoPlus and Diatos announce major strategic collaboration
	05.03	Biopharmaceutical company OctoPlus secures € 5.7 million to develop new products